Search Result

Results for "

Jurkat T lymphocytes

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Bacterial (1) Calcium Channel (1) CD28 (1) HIV (1) IFNAR (1) IMPDH (1) Integrin (4) Interleukin Related (2) Isotope-Labeled Compounds (3) Na+/K+ ATPase (1) NF-κB (1) Nuclear Factor of activated T Cells (NFAT) (1) PD-1/PD-L1 (2) Reference Standards (1) Src (1) TNF Receptor (1) TRP Channel (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (9)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19344

Lifitegrast 10+ Cited Publications SAR 1118; SHP-606	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344A

Lifitegrast sodium 10+ Cited Publications SAR 1118 sodium; SHP-606 sodium	Integrin	Inflammation/Immunology
Lifitegrast (SAR 1118) sodium is a potent integrin antagonist. Lifitegrast sodium blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast sodium inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast sodium can be used for researching dry eye disease .

HY-175087

D-myo-Inositol-1,2,4,5,6-pentaphosphate sodium salt Ins(1,2,4,5,6)P5 sodium salt; 1,2,4,5,6-IP5 sodium salt	Calcium Channel	Others
D-myo-Inositol-1,2,4,5,6-pentaphosphate (Ins(1,2,4,5,6)P5) sodium salt is one of several different inositol oligophosphate isomers involved in signal transduction. In human Jurkat T lymphocytes, Ins(1,2,4,5,6)P5 (sodium salt) is phosphorylated to InsP6 by 1/3 kinase. D-myo-Inositol-1,2,4,5,6-pentaphosphate sodium salt is involved in calcium signaling .

HY-137704

2′-Deoxy-ADPR	TRP Channel	Others
2′-Deoxy-ADPR is an agonist for transient receptor potential melastatin 2 channel (TRPM2 channel). 2′-Deoxy-ADPR may acts as the signaling molecule in Jurkat T-lymphocytes .

HY-118917

VX-148	IMPDH	Inflammation/Immunology
VX-148 is an orally active immunosuppressant, which is a non-competitive inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor with K_i values for IMPDH Ⅱ and IMPDH Ⅰ of 6 and 14 nM respectively. VX-148 can significantly inhibit the proliferation of human peripheral blood mononuclear cells (PBMC) stimulated by T-cell mitogen (PHA) or B-cell mitogen (SPAS). VX-148 has high selectivity for lymphocytes (such as L1210, Jurkat T cells, and Raji B cells), but has no significant toxicity to non-lymphoid cells. VX-148 can inhibit antibody responses in mouse models and significantly prolong the survival time of transplanted skin in allogeneic skin transplantation models. VX-148 can be used in the research of autoimmune diseases (such as rheumatoid arthritis, psoriasis) and organ transplantation anti-rejection .

HY-19344R

Lifitegrast (Standard) SAR 1118 (Standard); SHP-606 (Standard)	Reference Standards Integrin	Inflammation/Immunology
Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S2

Lifitegrast-d4-1	Isotope-Labeled Compounds Integrin	Inflammation/Immunology
Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Cancer
PL120131 is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors .

HY-19344S1

Lifitegrast-d6 SAR 1118-d₆; SHP-606-d₆	Isotope-Labeled Compounds	Inflammation/Immunology
Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4 SAR 1118-d₄; SHP-606-d₄	Isotope-Labeled Compounds	Inflammation/Immunology
Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-P10838A

PL120131 acetate	PD-1/PD-L1 Apoptosis	Cancer
PL120131 acetate is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors .

HY-N17413

(-)-γ-Cuparenol	Bacterial Na+/K+ ATPase NF-κB Nuclear Factor of activated T Cells (NFAT)	Cardiovascular Disease Infection Inflammation/Immunology
(-)-γ-Cuparenol is a sesquiterpene compound with an IC₅₀ of 23.6 μg/mL against porcine Na ⁺/K ⁺-ATPase. (-)-γ-Cuparenol reduces phytohemagglutinin (PHA)-induced activation of NF-AT and NF-κB in Jurkat cells. (-)-γ-Cuparenol inhibits the growth of Gram-positive bacteria and some Gram-negative bacteria. (-)-γ-Cuparenol exhibits weak inhibitory activity against Candida albicans. (-)-γ-Cuparenol is applicable for research related to immunoregulation, cardiovascular diseases and bacterial infections .

HY-181507

CD28-IN-3	CD28 IFNAR TNF Receptor Interleukin Related	Cancer
CD28-IN-3 is a CD28 inhibitor with an IC₅₀ of 7.80 μM and a Kd of 52.45 μM. CD28-IN-3 selectively blocks the CD28-B7 interaction, thereby inhibiting CD28-mediated costimulation. CD28-IN-3 suppresses the production of proinflammatory cytokines IFN-γ, IL-2 and TNF-α. CD28-IN-3 can be used in the research of checkpoint-resistant cancers .

HY-182566

ITI-367	HIV	Infection
ITI-367 is a HIV-1 inhibitor that targets the nuclear localization signal 1 (NLS-1) of HIV-1 matrix protein and the interaction between HIV-1 pre-integration complex (PIC) and importin-β. ITI-367 inhibits HIV-1 replication at the pre-integration stage, reduces the formation of 2-LTR circles, and sequesters viral DNA in the cytoplasm. ITI-367 can be used for the research of HIV infection .

HY-112448

Lck-IN-6	Src Interleukin Related	Inflammation/Immunology
Lck-IN-6 (Compound 12g) is a Lck inhibitor with an IC₅₀ of 3 nM. Lck-IN-6 inhibits the production of IL-2. Lck-IN-6 can be used in the research of rheumatoid arthritis and inflammatory bowel disease .

Cat. No.	Product Name	Target	Research Area

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Cancer
PL120131 is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors .

HY-P10838A

PL120131 acetate	PD-1/PD-L1 Apoptosis	Cancer
PL120131 acetate is a PD-1 antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N17413

(-)-γ-Cuparenol	Schisandra sphenanthera Rehd. et Wils Structural Classification Terpenoids Sesquiterpenes Plants Schisandraceae Source Classification	Bacterial Na+/K+ ATPase NF-κB Nuclear Factor of activated T Cells (NFAT)
(-)-γ-Cuparenol is a sesquiterpene compound with an IC₅₀ of 23.6 μg/mL against porcine Na ⁺/K ⁺-ATPase. (-)-γ-Cuparenol reduces phytohemagglutinin (PHA)-induced activation of NF-AT and NF-κB in Jurkat cells. (-)-γ-Cuparenol inhibits the growth of Gram-positive bacteria and some Gram-negative bacteria. (-)-γ-Cuparenol exhibits weak inhibitory activity against Candida albicans. (-)-γ-Cuparenol is applicable for research related to immunoregulation, cardiovascular diseases and bacterial infections .

Cat. No.	Product Name	Chemical Structure

HY-19344S2

Lifitegrast-d4-1
Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d4-1

Lifitegrast-d₄-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S1

Lifitegrast-d6
Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d6

Lifitegrast-d₆ (SAR 1118-d₆) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

HY-19344S

Lifitegrast-d4
Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Lifitegrast-d4

Lifitegrast-d₄ (SAR 1118-d₄) is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC₅₀ of 2.98 nM. Lifitegrast can be used for researching dry eye disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks